Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial.
Nazzareno Galiè,Marc Humbert,Jean-Luc Vachiery,Carmine Dario Vizza,Meinhard Kneussl,Alessandra Manes,Olivier Sitbon,Adam Torbicki,Marion Delcroix,Robert Naeije,Marius M. Hoeper,Ari Chaouat,Sophie Morand,Bruno Besse,Gérald Simonneau +14 more
TLDR
Beraprost improves exercise capacity and symptoms in NYHA functional class II and III patients with PAH and, in particular, in those with primary pulmonary hypertension.About:
This article is published in Journal of the American College of Cardiology.The article was published on 2002-05-01 and is currently open access. It has received 635 citations till now. The article focuses on the topics: Beraprost & Pulmonary hypertension.read more
Citations
More filters
Journal ArticleDOI
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).
Nazzareno Galiè,Marc Humbert,Jean-Luc Vachiery,Simon Gibbs,Irene Lang,Adam Torbicki,Gérald Simonneau,Andrew Peacock,Anton Vonk Noordegraaf,Maurice Beghetti,Ardeschir Ghofrani,Miguel Angel Gomez Sanchez,Georg Hansmann,Walter Klepetko,Patrizio Lancellotti,Marco Matucci,Theresa McDonagh,Luc Pierard,Pedro T. Trindade,Maurizio Zompatori,Marius M. Hoeper +20 more
TL;DR: In this paper, the authors defined the following terms: ALAT, alanine aminotransferase, ASAT, aspartate AMINOTE, and APAH, associated pulmonary arterial hypertension.
Journal ArticleDOI
Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)
Nazzareno Galiè,Marius M. Hoeper,Marc Humbert,Adam Torbicki,Jean-Luc Vachiery,J.A. Barberà,Maurice Beghetti,Paul A. Corris,Sean Gaine,J S R Gibbs,Miguel Ángel Gómez-Sánchez,Guillaume Jondeau,Walter Klepetko,Christian Opitz,Andrew J. Peacock,LJ Rubin,Michael J. Zellweger,Gérald Simonneau +17 more
TL;DR: In this paper, a review of the published evidence for management and/or prevention of a given condition is carried out by experts in the field and a critical evaluation of diagnostic and therapeutic procedures is performed including assessment of the risk/benefit ratio.
Journal ArticleDOI
ACC/AHA 2008 guidelines for the management of adults with congenital heart disease: Executive summary - A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (writing committee to develop guidelines for the management of adults with congenital heart disease)
Carole A. Warnes,Roberta G. Williams,Thomas M. Bashore,John S. Child,Heidi M. Connolly,Joseph A. Dearani,Pedro J. del Nido,James W. Fasules,Thomas P. Graham,Ziyad M. Hijazi,Sharon A. Hunt,Mary Etta King,Michael J. Landzberg,Pamela D. Miner,Martha J. Radford,Edward P. Walsh,Gary D. Webb +16 more
TL;DR: In this paper, the use of diagnostic procedures and therapies introduced and tested for detection, management, or prevention of disease is discussed. But, the focus is on the medical profession.
Journal ArticleDOI
Inhaled iloprost for severe pulmonary hypertension.
Horst Olschewski,Gérald Simonneau,Nazzareno Galiè,T. Higenbottam,Robert Naeije,Lewis J. Rubin,Sylvia Nikkho,Rudolf Speich,Marius M. Hoeper,Jürgen Behr,Jörg Winkler,Olivier Sitbon,Wladimir Popov,H. Ardeschir Ghofrani,Alessandra Manes,David G. Kiely,R Ewert,Andreas Meyer,Paul A. Corris,Marion Delcroix,Miguel Ángel Gómez-Sánchez,Harald Siedentop,Werner Seeger +22 more
TL;DR: Inhaled Iloprost is an effective therapy for patients with severe pulmonary hypertension and hemodynamic values were significantly improved at 12 weeks when measured after iloprost inhalation, and were significantly worse in the placebo group.
Journal ArticleDOI
Treatment of Pulmonary Arterial Hypertension
TL;DR: The evolution of therapy from vasodilators to antiproliferative agents reflects the advancement in the understanding of the mechanisms mediating pulmonary arterial hypertension.
References
More filters
Journal ArticleDOI
Psychophysical bases of perceived exertion
TL;DR: A presentation is made of ratio-scaling methods, category methods, especially the Borg Scale for ratings of perceived exertion, and a new method that combines the category method with ratio properties.
Journal ArticleDOI
An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation.
TL;DR: A balance between formation of anti- and pro-aggregatory substances by enzymes could also contribute to the maintenance of the integrity of vascular endothelium and explain the mechanism of formation of intra-arterial thrombi in certain physiopathological conditions.
Journal ArticleDOI
Survival in Patients with Primary Pulmonary Hypertension: Results from a National Prospective Registry
Gilbert E. D'Alonzo,Robyn J. Barst,Stephen M. Ayres,Edward H. Bergofsky,Bruce H. Brundage,Katherine M. Detre,Alfred P. Fishman,Roberta M. Goldring,Berton M. Groves,Janet T. Kernis,Paul S. Levy,Giuseppe G. Pietra,Lynne Reid,John T. Reeves,Stuart Rich,Carol E. Vreim,George W. Williams,Margaret Wu +17 more
TL;DR: Mortality was most closely associated with right ventricular hemodynamic function and can be characterized by means of an equation using three variables: mean pulmonary artery pressure, mean right atrial pressure, and cardiac index.
Journal ArticleDOI
A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension
Robyn J. Barst,Lewis J. Rubin,Walker Long,Michael D. McGoon,Stuart Rich,David B. Badesch,Bertron M. Groves,Victor F. Tapson,Robert C. Bourge,Bruce H. Brundage,Spencer K. Koerner,David Langleben,Cesar A. Keller,Srinivas Murali,Barry F. Uretsky,Linda M. Clayton,Maria M. Jöbsis,Shelmer D. Blackburn,Denise Shortino,James W. Crow +19 more
TL;DR: As compared with conventional therapy, the continuous intravenous infusion of epoprostenol produced symptomatic and hemodynamic improvement, as well as improved survival in patients with severe primary pulmonary hypertension.
Journal Article
The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure
Gordon H. Guyatt,Michael J. Sullivan,Penelope J. Thompson,Ernest L. Fallen,S. O. Pugsley,D W Taylor,Leslie B. Berman +6 more
TL;DR: It is concluded that the 6-minute walk is a useful measure of functional exercise capacity and a suitable measure of outcome for clinical trials in patients with chronic heart failure.
Related Papers (5)
A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension
Robyn J. Barst,Lewis J. Rubin,Walker Long,Michael D. McGoon,Stuart Rich,David B. Badesch,Bertron M. Groves,Victor F. Tapson,Robert C. Bourge,Bruce H. Brundage,Spencer K. Koerner,David Langleben,Cesar A. Keller,Srinivas Murali,Barry F. Uretsky,Linda M. Clayton,Maria M. Jöbsis,Shelmer D. Blackburn,Denise Shortino,James W. Crow +19 more
Inhaled iloprost for severe pulmonary hypertension.
Horst Olschewski,Gérald Simonneau,Nazzareno Galiè,T. Higenbottam,Robert Naeije,Lewis J. Rubin,Sylvia Nikkho,Rudolf Speich,Marius M. Hoeper,Jürgen Behr,Jörg Winkler,Olivier Sitbon,Wladimir Popov,H. Ardeschir Ghofrani,Alessandra Manes,David G. Kiely,R Ewert,Andreas Meyer,Paul A. Corris,Marion Delcroix,Miguel Ángel Gómez-Sánchez,Harald Siedentop,Werner Seeger +22 more